Jetzt 3-fach-Bonus sichern bei finanzen.net zero und dauerhaft Gebühren sparen!

Regulus Therapeutic Aktie

Kaufen

Verkaufen

Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Bei einem anderen Broker handeln

Div. Rendite0,00%

WKNA3DNZ4

ISINUS75915K3095

SymbolRGLS

Regulus Therapeutic Aktien News

Sortieren:Datum Meistgelesen

12.06.23PR NewswireRegulus Therapeutics Strengthens Research & Development Leadership

16.05.23PR NewswireRegulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

11.05.23PR NewswireRegulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates

13.04.23PR NewswireRegulus Therapeutics Announces $15 Million Private Placement of Equity

12.04.23PR NewswireRegulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant P...

23.03.23PR NewswireRegulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates

09.02.23PR NewswireRegulus Therapeutics to Present at the SVB Securities Global Biopharma Conference

13.01.23PR NewswireRegulus Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

12.12.22PR NewswireRegulus Therapeutics Announces Resignation of Board Member

29.11.22PR NewswireRegulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical Operations

10.11.22PR NewswireRegulus Therapeutics Reports Third Quarter 2022 Financial Results and Recent Updates

03.11.22PR NewswireRegulus Therapeutics Announces Timing for Third Quarter 2022 Financial Results Webcast and Conference Call

02.11.22PR NewswireRegulus Therapeutics Announces First Patient Dosed in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

27.10.22PR NewswireRegulus Therapeutics Announces Poster Presentation at ASN Kidney Week 2022

Regulus Therapeutic News

Regulus Therapeutic News: auf dieser Seite finden Sie alle Regulus Therapeutic News und Nachrichten zur Regulus Therapeutic Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Regulus Therapeutic News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Regulus Therapeutic News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.